(AP) — Protalix BioTherapeutics Inc. (PLX) on Tuesday reported profit of $4 million in its third quarter.
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Dror Bashan, President and Chief Executive Officer, is scheduled to present at the Stifel 2026 Healthcare Conference. The Conference is being held on November 10-12, 2026 at the Lotte New York Palace Hotel, New York City, NY.
Detailed price information for Protalix Biotherapeutics (PLX-A) from The Globe and Mail including charting and trades.
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Gilad Mamlok, Senior Vice President and Chief Financial Officer, is scheduled to participate in the following two upcoming investor conferences in New York City, New York:
Detailed price information for Protalix Biotherapeutics (PLX-A) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.